8-K: AEON Biopharma Announces Reverse Stock Split to Maintain NYSE Compliance

AEON Biopharma implements a 1-for-72 reverse stock split to boost its stock price and maintain compliance with NYSE American listing requirements.

Summary

• AEON Biopharma held a Special Meeting of Stockholders on February 24, 2025, where shareholders approved an amendment to the company's Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 500,000,000 to 1,040,000,000.
• Shareholders also granted the Board of Directors the discretion to effect a reverse stock split of the Common Stock at a ratio of 1-for-5 to 1-for-150.
• Following the meeting, the Board approved a 1-for-72 reverse stock split, which will be effective on February 26, 2025, at 12:01 a.m. Eastern Time.
• As a result of the reverse stock split, every 72 pre-split shares will be combined into one new share, reducing the number of outstanding shares from approximately 79.9 million to approximately 1.1 million.
• The trading symbol will remain 'AEON', but the CUSIP number will change to 00791X 209.
• No fractional shares will be issued; instead, they will be rounded up to the nearest whole share.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a reverse stock split is often viewed negatively, it's a necessary step for the company to maintain its listing and continue operations. The company is taking proactive steps to address compliance issues.

Positives

• The reverse stock split aims to increase the selling price of the company's common stock.
• Maintaining compliance with NYSE American listing requirements is crucial for continued trading on the exchange.
• Shareholders' ownership percentage will remain unchanged, except for fractional shares which will be rounded up.

Risks

• The company's ability to continue to meet continued stock exchange listing standards is a risk factor.
• The company may be adversely affected by other economic, business, regulatory, and/or competitive factors.

Future Outlook

The company will continue to trade on the NYSE American under the symbol 'AEON' with a new CUSIP number. The reverse stock split is intended to help maintain compliance with the exchange's listing requirements.

Management Comments

• The document does not contain direct quotes, but it implies management believes the reverse stock split is necessary to maintain NYSE American compliance.

Industry Context

Reverse stock splits are often used by companies whose stock price has fallen below exchange minimums, such as the NYSE American, to avoid delisting. This action is not uncommon in the biopharmaceutical industry, where companies can face volatility due to clinical trial outcomes and regulatory approvals.

Comparison to Industry Standards

• Many companies facing similar listing compliance issues have implemented reverse stock splits.
• For example, companies like BioTime and Ocugen have previously used reverse stock splits to regain compliance with Nasdaq listing requirements.
• The specific ratio of 1-for-72 is within the range (1-for-5 to 1-for-150) approved by shareholders, but the high end of the range suggests the company's stock price was under significant pressure.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they hold, but their percentage ownership will remain the same (excluding fractional shares).
• The reverse stock split aims to stabilize the company's stock price, which could benefit shareholders in the long term.
• The company's ability to remain listed on the NYSE American is important for maintaining investor confidence.

Next Steps

• File the Charter Amendment with the Secretary of State of the State of Delaware on February 25, 2025.
• The Reverse Stock Split will take legal effect at 12:01 A.M. Eastern Time on February 26, 2025.
• The Company's Common Stock will open for trading on the NYSE American on February 26, 2025, on a post-split basis.

Key Dates

Keywords

reverse stock split, common stock, AEON Biopharma, NYSE American, shareholders, certificate of incorporation